Response to 'The use of tenofovir in patients with COVID-19'
HIV Med
.
2022 Sep;23(8):929-930.
doi: 10.1111/hiv.13278.
Epub 2022 Feb 22.
Authors
Ming Jie Lee
1
2
,
Achyuta Nori
2
,
Sarah Fidler
1
,
Ranjababu Kulasegaram
2
,
Julie Fox
2
,
Colette Smith
3
;
RECEDE-C19 study
Affiliations
1
Imperial College London, Department of Infectious Disease, and Imperial College NHS Trust, London, UK.
2
Harrison Wing, Guys' and St Thomas' NHS Foundation Trust, London, UK.
3
Institute for Global Health, UCL, London, UK.
PMID:
35194929
PMCID:
PMC9111571
DOI:
10.1111/hiv.13278
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
HIV Infections* / drug therapy
Humans
Lamivudine / therapeutic use
Tenofovir / therapeutic use
Substances
Antiviral Agents
Lamivudine
Tenofovir
Grants and funding
MR/L00528X/1/MRC_/Medical Research Council/United Kingdom